ASCO 2024 | EAZ171: taxane-induced peripheral neuropathy in Black women with breast cancer

Lisa Carey • 31 May 2024

ASCO 2024

EAZ171

Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, presents results of the EAZ171 trial (NCT04001829), which examines the incidence of taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer undergoing (neo)adjuvant weekly paclitaxel or docetaxel. Germline genetic variations did not significantly impact TIPN risk but, weekly paclitaxel led to higher rates of grade 2-4 TIPN and dose reductions compared to every three-week docetaxel. These results suggest that docetaxel may be a more tolerable option for Black women, potentially improving treatment outcomes. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research Funding – AstraZeneca (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); NanoString Technologies (Inst); Novartis (Inst); Seagen (Inst); Veracyte (Inst)